Glomerulonephritis Market Expected To Grow At 4.7% CAGR Through 2030: What Businesses Need To Know

Glomerulonephritis Market Report

Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.

Glomerulonephritis Market Value Growth And Long-Term Outlook

The glomerulonephritis market has observed consistent expansion over recent years. Projections indicate it will rise from $11.61 billion in 2025 to $12.18 billion in 2026, achieving a compound annual growth rate (CAGR) of 5.0%. Historically, this growth is attributable to factors such as the prevalence of autoimmune disorders, the adoption of kidney biopsies, the expansion of nephrology clinics, the availability of immunosuppressive drugs, and the broadening of diagnostic laboratory services.

The glomerulonephritis market is anticipated to exhibit sustained expansion over the coming years. It is predicted to reach a valuation of $14.66 billion by 2030, growing at a compound annual growth rate (CAGR) of 4.7%. This projected growth throughout the forecast period stems from breakthroughs in renal diagnostics, the evolution of precision nephrology, a rise in the prevalence of chronic kidney disease, the broadening of specialized nephrology care, and better patient adherence to treatment. Noteworthy trends for the same period include a heightened emphasis on the early detection of kidney disease, an increasing application of immunosuppressive therapies, the rising integration of biomarker-based testing, the expansion of dialysis support services, and enhanced chronic disease management strategies.

Get A Free Sample Report With In-Depth Market Insights:

https://thebusinessresearchcompany.com/sample_request?id=30691962&type=smp&name=Glomerulonephritis%20Market%20Report%202026&utm_source=Blogs&utm_medium=Paid&utm_campaign=Nov_PR

Glomerulonephritis Market Expansion Drivers: What’s Shaping Future Growth?

The increasing incidence of kidney disorders is anticipated to propel the expansion of the glomerulonephritis market in the foreseeable future. Kidney disorders encompass a spectrum of conditions that impact the structure or function of the kidneys, leading to impaired filtration, waste elimination, and proper fluid balance. The growing occurrence of these disorders is attributed to factors such as aging populations, escalating rates of chronic diseases like diabetes and hypertension, and various lifestyle choices. Kidney ailments contribute to glomerulonephritis by triggering immune system dysregulation, persistent inflammation, or structural damage, which subsequently compromises kidney filtration and overall function. For instance, in June 2023, according to Kidney Research UK, a UK-based charitable organization dedicated to research and advocacy for improving the understanding, prevention, and treatment of kidney diseases, an estimated 7.19 million people in the UK were affected by chronic kidney disease in 2023, representing over 10% of the UK population, with projections indicating an increase to 7.61 million people by 2033. Hence, the rising prevalence of kidney disorders is poised to drive the growth of the glomerulonephritis market.

Glomerulonephritis Market Segment Analysis: What Are The Core Market Categories?

The glomerulonephritis market covered in this report is segmented –

1) By Type: Acute Glomerulonephritis, Chronic Glomerulonephritis

2) By Diagnosis: Urine And Blood Tests, Imaging Tests, Kidney Biopsy, Other Diagnosis

3) By Treatment: Medication, Surgery, Dialysis, Other Treatments

4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Other Distribution Channels

5) By End-User: Hospitals, Specialty Clinics, Other End-Users

Subsegments:

1) By Acute Glomerulonephritis: Post-infectious Glomerulonephritis, IgA Nephropathy, Lupus Nephritis, Rapidly Progressive Glomerulonephritis (RPGN), Goodpasture Syndrome

2) By Chronic Glomerulonephritis: Focal Segmental Glomerulosclerosis (FSGS), Membranous Nephropathy, Minimal Change Disease, Alport Syndrome, Diabetic Nephropathy, Hypertensive Nephrosclerosis

Glomerulonephritis Market Industry Trends Fueling Future Revenue Growth

Major companies in the glomerulonephritis market are prioritizing the development of advanced non-immunosuppressive treatments to address current medical needs and improve patient results. Non-immunosuppressive treatments are therapies designed not to weaken or suppress the immune system, aiming to treat conditions without compromising immune function. For example, in September 2024, Travere Therapeutics Inc., a US-based biopharmaceutical company, introduced FILSPARI (sparsentan), which received approval from the Food and Drug Administration (FDA) for treating IgA nephropathy, a specific kidney disease. This drug is the only non-immunosuppressive treatment demonstrated to significantly slow the decline in kidney function for these patients. The approval of FILSPARI signifies a major breakthrough in managing IgA nephropathy, which is identified as the most common form of primary glomerulonephritis. This therapy offers a new choice for patients who previously had limited options. This approval highlights Travere’s dedication to improving patient outcomes in kidney disease.

Glomerulonephritis Market Top Companies Driving Competitive Growth

Major companies operating in the glomerulonephritis market are Pfizer Inc., F. Hoffmann-La Roche Ltd., AstraZeneca PLC, Novartis International AG, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Apellis Pharmaceuticals Inc., MorphoSys AG, Travere Therapeutics Inc., Vera Therapeutics Inc., Calliditas Therapeutics AB, Omeros Corporation, Otsuka Pharmaceutical Co. Ltd., Aurinia Pharmaceuticals Inc., Alexion Pharmaceuticals Inc., Anthera Pharmaceuticals Inc., Chinook Therapeutics, Purespring Therapeutics, Walden Biosciences, Visterra Inc.

View The Full Glomerulonephritis Market Report:

https://thebusinessresearchcompany.com/report/glomerulonephritis-global-market-report?utm_source=Blogs&utm_medium=Paid&utm_campaign=Nov_PR

Glomerulonephritis Market Regional Analysis: Which Geography Leads On Revenue?

North America was the largest region in the glomerulonephritis market in 2025. The regions covered in the glomerulonephritis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Reach Out To Our Team:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model